Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Alumis Inc. · ALMS · Third quarter 2026

Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path

Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.

16 Nov 2026 · CompePharma editorial
$1.9 million (vs $2.1 million in Q3 2025)Q3 2026 collaboration revenue
$80.8 million (vs $97.8 million)Q3 2026 R&D expenses
$94.9 million (vs $110.8 million)Q3 2026 net loss
$431.3 millionCash, equivalents and marketable securities, Sept. 30, 2026
54%Week 48 PASI 100 response, ONWARD program

The quarter in numbers

Alumis reported Q3 2026 revenue of $1.9 million, all collaboration revenue tied to its agreement with Kaken Pharmaceutical, against $2.1 million a year earlier. For a pre-commercial company this line is incidental. The story is the cost base.

Operating expenses were $100.98 million, down from $117.36 million in Q3 2025, leaving a loss from operations of $99.08 million versus $115.29 million. Interest income was $4.3 million, against $4.6 million a year earlier. Net loss was $94.9 million, compared with $110.8 million in the prior-year quarter.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
CorMedix Inc. · CRMD · Third quarter 2026

CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook

$54.5 millionQ3 2026 consolidated revenue$17.2 millionDefenCath net revenue$14.7 millionQ3 2026 net loss

Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.

17 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Iambic Therapeutics, Inc. · IAM · Third quarter 2026

Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn

$11.4 million (vs $4.7 million in Q3 2025)Q3 2026 collaboration revenue$34.1 million (vs $23.1 million)Q3 2026 R&D expenses$38.5 million (vs $21.5 million)Q3 2026 net loss

Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.

16 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Ionis Pharmaceuticals Inc · IONS · Third quarter 2026

Ionis lowers TRYNGOLZA outlook to ~$50M as DAWNZERA and partners carry Q3

$243 million (vs $157 million)Q3 2026 total revenue$9 millionQ3 TRYNGOLZA net sales$37 millionQ3 DAWNZERA net sales

Ionis reaffirmed total revenue, operating loss and cash guidance, but cut 2026 TRYNGOLZA sales to about $50 million from $100-110 million as its first large-indication launch ramps more slowly.

16 Nov 2026 · CompePharma editorial